Table 4

Risk of CIMP+ and CIMP− colorectal cancer (CRC) according to the methylenetetrahydrofolate reductase (MTHFR ) genotype

Females* (n=118)Males* (n=109)
*Odds ratio and 95% confidence interval for frequency of the CT or TT genotype in CRC patients compared with age matched control group.
†Defined as having two or more CpG sites methylated.
‡p=0.037.
CIMP+, CpG island methylator phenotype.
Controls v all CRC1.13 (0.75–1.71)0.92 (0.60–1.39)
Controls v CIMP+†2.17 (1.03–4.57)‡0.68 (0.32–1.42)
Controls v CIMP−0.84 (0.52–1.35)†1.03 (0.60–1.39)